Compound | Dose | Target | Effects | Model | Cell line | Ref |
---|---|---|---|---|---|---|
Epigallocatechin gallate (EGCG) and polyphenols E | 0–50 µg/ml | HPV-E7 | Inhibited immortalized cervical epithelial and cancer cell growth, apoptosis is induced by EGCG in a dose-dependent statistically | In-vitro | TCL1, HeLa, Me180 | [27] |
EGCG | 250–500 µM | - | Induced cell cycle arrest and apoptosis, Inhibited cell Growth | In-vitro | HeLa, C33A, WI-38 | [28] |
EGCG | 25 µM | NFκB p65, COX-2, p-Akt, p-mTOR | Inhibited growth of cervical cancer cells, inhibited cell survival and induced apoptosis | In-vitro | HeLa | [29] |
Sinecatechins | 160 to 360µM | - | Inhibited cancer cell growth, induced apoptosis, mediated by cell cycle deregulation | In-vitro | CaSki, SiHa, HeLa, C4-I | [30] |
Green tea | - | - | A protective factor against cervical cancer | Human | - | [31] |
Polyphenon E | 800Â mg | CIN1 | Did not promote the clearance of persistent high-risk HPV and related CIN1 | Human | - | [32] |
EGCG | 60 µg/mL | - | Cytostatic but not cytotoxic effect | In-vitro | HeLa | [33] |
EGCG | 1-100 µM | MMP-9, TIMP-1 | Induced apoptosis and inhibited invasion and migration | In-vitro | HeLa | [34] |
epigallocatechin-3-gallate | 50 µg/ml | SOD, GPx | Free radical scavenging properties, protected the proliferation of cancerous cells and boosted the activity of SOD and GPx | In-vitro, human | HeLa | [35] |
EGCG | 35 µM | - | Inhibited cervical cancer cell growth through induction of apoptosis and cell cycle arrest | In-vitro | CaSki | [36] |
EGCG | 0, 25, 50 µM | - | Inhibited proliferation, induced cell cycle arrest | In-vitro | HeLa | [37] |
EGCG | 25 µM | DNMT3B | Reversed expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases | In-vitro | HeLa | [38] |
EGCG | 25 or 50 µM | p53 | Suppressed Fused Toes Homolog protein | In-vitro | HeLa | [39] |
EGCG | 25–100 µg/ml | cyclinD1, LIMD1, RBSP3, p16, DNMT1 | Inhibited cellular proliferation, Induced apoptosis | In-vitro | HeLa | [40] |
Catechin hydrate (CH) | 50–600 lg/mL | tp53, caspase-3, -8, -9 | Inhibited proliferation and mediated apoptosis | In-vitro | SiHa | [41] |
Tea extract and EGCG | 0-100 µM /L | TGF-β | Suppressed TGF-β-induced EMT, decreased ROS levels | In-vitro | Hela, SiHa | [42] |
EGCG | 50–100 µM | DNMT, HDAC, HMT, H3K9 | Decreased global DNA methylation | In-vitro | HeLa | [43] |
EGCG | 10 µM | - | Affected proliferation, adhesion and motility | In-vitro | HeLa | [44] |
EGCG, tea polyphenol | 0–100 mM | IGF-IR | Inhibited the proliferation, induced cell apoptosis | In-vitro | OMC-4, TMCC-1 | [45] |
EGCG | 0-100 µg/ml | miR-203, miR-125b | Inhibited cell proliferation | In-vitro | HeLa, CaSki, C33A | [46] |
EGCG | 0-100 µM | - | Antiproliferative effects | In-vitro | HeLa and TMCC-1 | [47] |
EGCG | 25, 50 µM | - | Inhibited Cell growth and poliferation | In-vitro | CaSki, HeLa | [48] |
EGCG | 5, 10 µg/ml | caspase-3 | Increased number of apoptotic cells | In-vitro | PBMCs | [49] |
Green tea extract, EGCG | 80 µg/mL, 100 µmol/L | VEGF | Abolished cell migration | In-vitro | HeLa, HepG2 | [50] |